Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%
Management Admin

Hemostemix Leadership Attending Abundance360 Summit

By The Northwire Desk — AI Analysis Mar 09, 2026 · 11:24 HEM · 0.08 Hemostemix Inc.
HEM · Price

Executive Summary

  • Hemostemix Inc. CEO Thomas Smeenk and Chairman Peter Lacey are attending the 2026 Abundance360 Summit in Los Angeles.
  • The executives will meet with investors and longevity‑focused participants to discuss the company’s ACP‑01 (VesCell) regenerative treatment and commercialization opportunities in Florida and The Bahamas.

Key Details

  • Attendance at the Abundance360 Summit, an event focused on biotechnology, AI, longevity science, and other exponential technologies.
  • Hemostemix will present its ACP‑01 (VesCell) therapy, which aims to improve microvascular circulation and promote vascular regeneration.
  • The company highlights 11 peer‑reviewed publications covering conditions such as angina, ischemic cardiomyopathy, dilated cardiomyopathy, and chronic limb‑threatening ischemia.
  • Executives will discuss potential shareholder participation in the commercialization stage of ACP‑01.

Notable Quotes

“Abundance360 is an incredible event,” said Thomas Smeenk, President and CEO of Hemostemix. “The conversations about commercialization in Florida and The Bahamas are generating significant interest…”

Read the original news release →

More from Hemostemix Inc.

Jun 26, 2026 · 08:48

Pre-revenue stem cell therapy developer advancing ACP-01 across ischemic indications while navigating severe liquidity constraints and ongoing dilutive financings.

Financings Jun 17, 2026 · 17:23

Micro-cap Biotech Cuts Financing Price in Half Amid Restatement and Going Concern Warnings

Financings Feb 03, 2026 · 19:02

Hemostemix appoints Hsiang as business consultant

Management Feb 03, 2026 · 08:56

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Management Jan 16, 2026 · 16:06

Hemostemix gets FDA support for basket protocol

Regulatory Jan 16, 2026 · 12:27

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Regulatory